{"id":21,"date":"2023-05-02T09:59:41","date_gmt":"2023-05-02T00:59:41","guid":{"rendered":"https:\/\/www-user.yokohama-cu.ac.jp\/~pharmac\/?page_id=21"},"modified":"2026-04-15T15:30:41","modified_gmt":"2026-04-15T06:30:41","slug":"publications","status":"publish","type":"page","link":"https:\/\/www-user.yokohama-cu.ac.jp\/~pharmac\/publications\/","title":{"rendered":"\u7814\u7a76\u696d\u7e3e"},"content":{"rendered":"\n

\u7814\u7a76\u696d\u7e3e<\/h2>\n\n\n\n

2026<\/strong><\/h3>\n\n\n\n

\u539f\u8457\u8ad6\u6587<\/strong><\/p>\n\n\n\n

    \n
  1. Masukawa D, Rei Tajika, Ichimaru Y, Kurihara M, Suzuki T, Goshima Y. Enhanced effect of the hallucinogen DOI in L-DOPA receptor Gpr143<\/em>-deficient mice. J Pharmacol Sci<\/em><\/strong>. 2026. 161(2): 32-35. <\/li>\n\n\n\n
  2. Shibata T, Bhat S, Cao D, Saito S, Khan N, Bernstein EA, Tokudome T, Okwan-Duodu D, Tourtellotte WG, Bernstein KE, Khan Z. Bioengineered iPSC-derived human macrophages with increased angiotensin-converting enzyme (ACE) expression suppress solid tumor growth. Signal Transduct Target Ther<\/em><\/strong>. 2026. 11(1):132. doi: 10.1038\/s41392-026-02650-3.<\/li>\n\n\n\n
  3. Nakamura T, Shibata T, Ito KI. EpCAM silencing suppresses aggressive phenotypes and induces partial redifferentiation in anaplastic thyroid cancer cells. PLoS One<\/em><\/strong>. 2026. 21(3):e0344276. doi: 10.1371\/journal.pone.0344276.<\/li>\n\n\n\n
  4. Inoue Y, Ishii A, Ishimura T, Yamada H, Sugioka S, Handa T, Ikushima A, Nishio H, Kato Y, Ohno S, Nakagawa Y, Kuwahara K, Matsusaka T, Tokudome T, Yanagita M, Yokoi H. Finerenone ameliorates diabetic kidney disease exacerbated by deletion of natriuretic peptide\/guanylyl cyclase-A signaling and dietary high-protein load. Sci Rep<\/em><\/strong>., 15(1):41378, 2025. doi: 10.1038\/s41598-025-25362-0.<\/li>\n\n\n\n
  5. Goshima Y, Nakamura H, Koga M, Koyama J, Kimura Y, Vasishth MN, Snyder EY, Asai M, Sakai K, Masukawa <\/strong>D. Disruption of the l-DOPA Receptor Gpr143\/OA1<\/em>-Gene in Mice Creates a Unique Mixed Psychosis-Like Phenotype. Neuropsychopharmacol Rep.<\/em><\/strong>, 46(1):e70080, 2026. doi:10.1002\/npr2.70080.<\/li>\n<\/ol>\n\n\n\n

    \u5b66\u4f1a\u767a\u8868<\/strong><\/p>\n\n\n\n

      \n
    1. \u5e02\u5ddd \u83dc\u3005\u5b50\u3001\u67f4\u7530 \u667a\u535a\u3001\u5897\u5ddd \u592a\u8f1d\u3001\u5409\u7530 \u5149\u4e00\u3001\u5fb3\u7559 \u5065\u3001\u300c\u5fc3\u623f\u6027\u30ca\u30c8\u30ea\u30a6\u30e0\u5229\u5c3f\u30da\u30d7\u30c1\u30c9\u306f\u816b\u760d\u8840\u7ba1\u306e\u6210\u719f\u5316\u3092\u4fc3\u9032\u3057\u3001\u8ee2\u79fb\u3092\u6291\u5236\u3059\u308b\u300d\u3001\u7b2c99\u56de\u65e5\u672c\u85ac\u7406\u5b66\u4f1a\u5e74\u4f1a\u30012026\u5e743\u670816\u65e5\u30011-YIA-B-04 (\u5b66\u90e8\u5b66\u751f\u512a\u79c0\u767a\u8868\u8cde\u53d7\u8cde)<\/strong><\/li>\n\n\n\n
    2. \u7a0b \u6668\u3001\u8d64\u5742 \u706f\u9999\u3001\u6df1\u7530 \u512a\u5e0c\u3001\u5897\u5ddd \u592a\u8f1d\u3001\u5fb3\u7559 \u5065\u3001\u300c\u8133\u5185\u30a2\u30f3\u30b8\u30aa\u30c6\u30f3\u30b7\u30f3\u2161\u30b7\u30b0\u30ca\u30eb\u306b\u3088\u308b\u5fc3\u80a5\u5927\u30e1\u30ab\u30cb\u30ba\u30e0\u306e\u89e3\u660e\u300d\u3001\u7b2c99\u56de\u65e5\u672c\u85ac\u7406\u5b66\u4f1a\u5e74\u4f1a\u30012026\u5e743\u670817\u65e5\u30012-YIA-DC-01<\/li>\n\n\n\n
    3. \u5897\u5ddd \u592a\u8f1d\u3001\u67f4\u7530 \u667a\u535a\u3001\u5409\u7530 \u5149\u4e00\u3001\u5897\u7530 \u62d3\u3001\u7a0b \u6668\u3001\u5713\u8c37 \u7814\u4eba\u3001\u5fb3\u7559 \u5065\u3001\u300c\u8133\u5185\u5fc3\u623f\u6027\u30ca\u30c8\u30ea\u30a6\u30e0\u5229\u5c3f\u30da\u30d7\u30c1\u30c9\u30b7\u30b0\u30ca\u30eb\u306f\u5fc3\u7b4b\u6897\u585e\u5f8c\u306e\u5fc3\u81d3\u30ea\u30e2\u30c7\u30ea\u30f3\u30b0\u3092\u6539\u5584\u3059\u308b\u300d\u3001\u7b2c99\u56de\u65e5\u672c\u85ac\u7406\u5b66\u4f1a\u5e74\u4f1a\u30012026\u5e743\u670817\u65e5\u30012-O-04<\/li>\n\n\n\n
    4. \u5713\u8c37 \u7814\u4eba\u3001\u5897\u5ddd \u592a\u8f1d\u3001\u67f4\u7530 \u667a\u535a\u3001\u5409\u7530 \u5149\u4e00\u3001\u5897\u7530 \u62d3\u3001\u7a0b \u6668\u3001\u5fb3\u7559 \u5065\u3001\u300c\u30de\u30a6\u30b9\u306b\u304a\u3051\u308b\u5fc3\u7b4b\u6897\u585e\u5f8c\u306e\u6027\u5dee\u4f9d\u5b58\u7684\u306a\u795e\u7d4c\u514d\u75ab\u5fdc\u7b54\u300d\u3001\u7b2c99\u56de\u65e5\u672c\u85ac\u7406\u5b66\u4f1a\u5e74\u4f1a\u30012026\u5e743\u670817\u65e5\u30012-YIA-DC-05\u3001(\u5e74\u4f1a\u512a\u79c0\u767a\u8868\u8cde(DC))<\/strong><\/li>\n\n\n\n
    5. \u5409\u7530 \u5149\u4e00\u3001\u5897\u5ddd \u592a\u8f1d\u3001\u67f4\u7530 \u667a\u535a\u3001\u5fb3\u7559 \u5065\u3001\u300c\u8133\u5185\u30b0\u30ec\u30ea\u30f3\u30b7\u30b0\u30ca\u30eb\u306f\u5fc3\u7b4b\u6897\u585e\u30e2\u30c7\u30eb\u30de\u30a6\u30b9\u306e\u75c5\u614b\u3092\u6539\u5584\u3059\u308b\u300d\u3001\u7b2c99\u56de\u65e5\u672c\u85ac\u7406\u5b66\u4f1a\u5e74\u4f1a\u30012026\u5e743\u670817\u65e5\u30012-O-11<\/li>\n\n\n\n
    6. \u5009\u91d1 \u821e\u3001\u67f4\u7530 \u667a\u535a\u3001\u5897\u5ddd \u592a\u8f1d\u3001\u5409\u7530 \u5149\u4e00\u3001\u5fb3\u7559 \u5065\u3001\u300c\u8133\u5185\u30b0\u30ec\u30ea\u30f3\u30b7\u30b0\u30ca\u30eb\u306f\u6557\u8840\u75c7\u30e2\u30c7\u30eb\u30de\u30a6\u30b9\u306e\u672b\u68a2\u81d3\u5668\u306b\u304a\u3051\u308b\u904e\u5270\u708e\u75c7\u3092\u6291\u5236\u3059\u308b\u300d\u3001\u7b2c99\u56de\u65e5\u672c\u85ac\u7406\u5b66\u4f1a\u5e74\u4f1a\u30012026\u5e743\u670817\u65e5\u30012-YIA-B-26<\/li>\n\n\n\n
    7. \u67f4\u7530 \u667a\u535a\u3001\u5897\u5ddd \u592a\u8f1d\u3001\u5409\u7530 \u5149\u4e00\u3001\u5fb3\u7559 \u5065\u3001\u300c\u8133\u5185\u30b0\u30ec\u30ea\u30f3\u30b7\u30b0\u30ca\u30eb\u306f\u6297\u816b\u760d\u514d\u75ab\u3092\u6d3b\u6027\u5316\u3057\u3001\u304c\u3093\u8ee2\u79fb\u3092\u6291\u5236\u3059\u308b\u300d\u3001\u7b2c99\u56de\u65e5\u672c\u85ac\u7406\u5b66\u4f1a\u5e74\u4f1a\u30012026\u5e743\u670818\u65e5\u30013-P-002<\/li>\n<\/ol>\n\n\n\n

      2025<\/strong><\/h3>\n\n\n\n

      \u539f\u8457\u8ad6\u6587<\/strong><\/p>\n\n\n\n

        \n
      1. Chang CY, Hern\u00e1ndez-Armengol R, Paul K, Lee JY, Nance K, Shibata T, Yue P, Stehlik C, Gibb DR. The Nrf2 Activator CDDO-Imidazole Suppresses Inflammation-Induced Red Blood Cell Alloimmunization. Antioxidants<\/em><\/strong>., 14(6):678, 2025.<\/li>\n\n\n\n
      2. Ishimura T, Osaki K, Sugioka S, Ishii A, Yamada H, Toda N, Ohno S, Kato Y, Matsusaka T, Tokudome T, Yanagita M, Yokoi H. Matrix metalloproteinase-(MMP)10 aggravates podocyte injury in glomerulonephritis. Nephrol Dial Transplant<\/em><\/strong>., 40(10):1961-1976, 2025.<\/li>\n\n\n\n
      3. Saito S, Cao DY, Bernstein EA, Shibata T, Jones AE, Rios A, Hoshi AO, Stotland AB, Nishi EE, Van Eyk JE, Divakaruni A, Khan Z, Bernstein KE. Peroxisome proliferator-activated receptor alpha is an essential factor in enhanced macrophage immune function induced by angiotensin-converting enzyme. Cell Mol Immunol<\/em><\/strong>., 22(3):243-259, 2025.<\/li>\n\n\n\n
      4. Saito S, Cao DY, Shibata T, Liu Y, Otagiri-Hoshi A, Cui X, Bernstein KE., Tumor derived cell-free nucleic acid upregulates programmed death-ligand 1 expression in neutrophil via intracellular Toll-like receptor signaling. Cancer Commun<\/em><\/strong>., 45(1):4-8, 2025.<\/li>\n<\/ol>\n\n\n\n

        \u7dcf\u8aac<\/strong><\/p>\n\n\n\n

          \n
        1. \u7532\u72b6\u817a\u764c\u306e\u5206\u5b50\u6a19\u7684\u6cbb\u7642\u8010\u6027\u30e1\u30ab\u30cb\u30ba\u30e0\u3001BIO Clinica<\/em><\/strong>, 40(11) 60-62, 2025. 2025\u5e7410\u6708\u53f7<\/li>\n\n\n\n
        2. \u4e73\u764c\u306e\u85ac\u5264\u8010\u6027\u5316\u6a5f\u69cb\u306e\u89e3\u660e\u3068\u514b\u670d\u6cbb\u7642\u6cd5\u306e\u5275\u51fa\u7814\u7a76\u3001Medical Science Diges<\/em><\/strong>t, 51(10) 34-36, 2025. 2025\u5e749\u6708\u53f7<\/li>\n\n\n\n
        3. \u5897\u5ddd \u592a\u8f1d,\u300c\u8133-\u5fc3\u81d3-\u514d\u75ab\u9023\u95a2\u300d\u306b\u7740\u76ee\u3057\u3066\u96e3\u6cbb\u6027\u5fc3\u75be\u60a3\u306e\u75c5\u614b\u3092\u8003\u3048\u308b, Precision Medicine<\/em><\/strong>, 2025\u5e749\u6708\u53f7, 2025.<\/li>\n<\/ol>\n\n\n\n

          \u5b66\u4f1a\u767a\u8868<\/strong><\/p>\n\n\n\n

            \n
          1. \u5897\u5ddd\u592a\u8f1d\u3001\u5fb3\u7559\u5065\u3001\u8ff7\u8d70\u795e\u7d4c\u7bc0-\u8ff7\u8d70\u795e\u7d4c\u80cc\u5074\u904b\u52d5\u6838\u9593\u795e\u7d4c\u56de\u8def\u306f\u5727\u53d7\u5bb9\u5668\u53cd\u5c04\u3092\u5fae\u8abf\u6574\u3059\u308b\u3001\u7b2c29\u56de\u65e5\u672c\u5fc3\u8840\u7ba1\u5185\u5206\u6ccc\u4ee3\u8b1d\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012025\u5e749\u670828\u65e5\u3001P-23\uff08\u30dd\u30b9\u30bf\u30fc\u767a\u8868\u8cde\uff09<\/strong><\/li>\n\n\n\n
          2. \u7a0b\u6668\u3001\u8d64\u5742\u706f\u9999\u3001\u6df1\u7530\u512a\u5e0c\u3001\u5897\u5ddd\u592a\u8f1d\u3001\u5fb3\u7559\u5065\u3001\u8133\u5185\u30a2\u30f3\u30b8\u30aa\u30c6\u30f3\u30b7\u30f3 II \u30b7\u30b0\u30ca\u30eb\u304c\u5fc3\u80a5\u5927\u306b\u4e0e\u3048\u308b\u5f71\u97ff\u306e\u89e3\u660e\u3001\u7b2c29\u56de\u65e5\u672c\u5fc3\u8840\u7ba1\u5185\u5206\u6ccc\u4ee3\u8b1d\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012025\u5e749\u670828\u65e5\u3001P-19<\/li>\n\n\n\n
          3. \u67f4\u7530\u667a\u535a\u3001\u5897\u5ddd\u592a\u8f1d\u3001\u5409\u7530\u5149\u4e00\u3001\u5fb3\u7559\u5065\u3001\u30a2\u30f3\u30b8\u30aa\u30c6\u30f3\u30b7\u30f3\u5909\u63db\u9175\u7d20\u306f\u30de\u30af\u30ed\u30d5\u30a1\u30fc\u30b8\u306e\u6297\u816b\u760d\u6d3b\u6027\u3092\u5897\u5f37\u3059\u308b\u3001\u7b2c29\u56de\u65e5\u672c\u5fc3\u8840\u7ba1\u5185\u5206\u6ccc\u4ee3\u8b1d\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012025\u5e749\u670828\u65e5\u3001P-18\uff08\u30dd\u30b9\u30bf\u30fc\u767a\u8868\u8cde\uff09<\/strong><\/li>\n\n\n\n
          4. \u67f4\u7530\u667a\u535a\u3001\u5897\u5ddd\u592a\u8f1d\u3001\u5409\u7530\u5149\u4e00\u3001\u5fb3\u7559\u5065\u3001\u8133\u5185\u30b0\u30ec\u30ea\u30f3\u30b7\u30b0\u30ca\u30eb\u306f\u816b\u760d\u514d\u75ab\u3092\u6d3b\u6027\u5316\u3057\u3001\u304c\u3093\u8ee2\u79fb\u3092\u6291\u5236\u3059\u308b\u3001\u7b2c29\u56de\u65e5\u672c\u5fc3\u8840\u7ba1\u5185\u5206\u6ccc\u4ee3\u8b1d\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012025\u5e749\u670828\u65e5\u3001P-17<\/li>\n\n\n\n
          5. \u5e02\u5ddd\u83dc\u3005\u5b50\u3001\u67f4\u7530\u667a\u535a\u3001\u5897\u5ddd\u592a\u8f1d\u3001\u5409\u7530\u5149\u4e00\u3001\u5fb3\u7559\u5065\u3001Atrial Natriuretic Peptide \u306f\u816b\u760d\u8840\u7ba1\u306e\u6210\u719f\u5316\u3092\u8a98\u5c0e\u3059\u308b\u3001\u7b2c29\u56de\u65e5\u672c\u5fc3\u8840\u7ba1\u5185\u5206\u6ccc\u4ee3\u8b1d\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012025\u5e749\u670828\u65e5\u3001P-16<\/li>\n\n\n\n
          6. \u5009\u91d1\u821e\u3001\u67f4\u7530\u667a\u535a\u3001\u5897\u5ddd\u592a\u8f1d\u3001\u5409\u7530\u5149\u4e00\u3001\u5fb3\u7559\u5065\u3001\u8133\u5185\u30b0\u30ec\u30ea\u30f3\u30b7\u30b0\u30ca\u30eb\u306f\u6557\u8840\u75c7\u30e2\u30c7\u30eb\u30de\u30a6\u30b9\u306e\u708e\u75c7\u53cd\u5fdc\u3092\u6291\u5236\u3059\u308b\u3001\u7b2c29\u56de\u65e5\u672c\u5fc3\u8840\u7ba1\u5185\u5206\u6ccc\u4ee3\u8b1d\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012025\u5e749\u670828\u65e5\u3001P-14<\/li>\n\n\n\n
          7. \u5897\u5ddd\u592a\u8f1d\u3001\u67f4\u7530\u667a\u535a\u3001\u5409\u7530\u5149\u4e00\u3001\u7a0b\u6668\u3001\u5897\u7530\u62d3\u3001\u5fb3\u7559\u5065\u3001\u8133\u5185\u708e\u75c7\u3092\u6a19\u7684\u3068\u3057\u305f\u5fc3\u7b4b\u6897\u585e\u306e\u753b\u671f\u7684\u6cbb\u7642\u6cd5\u958b\u767a\u3001\u7b2c29\u56de\u65e5\u672c\u5fc3\u8840\u7ba1\u5185\u5206\u6ccc\u4ee3\u8b1d\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012025\u5e749\u670828\u65e5\u3001P-13<\/li>\n\n\n\n
          8. \u67f4\u7530\u667a\u535a\u3001\u96e3\u6cbb\u6027\u304c\u3093\u306e\u85ac\u5264\u8010\u6027\u514b\u670d\u3092\u76ee\u6307\u3057\u305f\u753b\u671f\u7684\u6cbb\u7642\u6cd5\u306e\u5275\u51fa\u7814\u7a76\u3001\u7b2c84\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012025\u5e749\u670825\u65e5\u3001YIA1-4<\/li>\n\n\n\n
          9. \u67f4\u7530\u667a\u535a\u3001\u5897\u5ddd \u592a\u8f1d\u3001\u5409\u7530 \u5149\u4e00\u3001\u5fb3\u7559 \u5065\u3001ANP\u306f\u816b\u760d\u8840\u7ba1\u306e\u6210\u719f\u5316\u3092\u4fc3\u9032\u3059\u308b\u3001\u7b2c98\u56de\u65e5\u672c\u5185\u5206\u6ccc\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012025\u5e746\u67086\u65e5\u3001O2-7-21<\/li>\n\n\n\n
          10. Tomohiro \bShibata, Daiki Masukawa, Koichi Yoshida, Takeshi Tokudome, ANP promotes maturation of tumor blood vessels, APPW2025, 2025\u5e743\u670819\u65e5, 3017m-04<\/li>\n\n\n\n
          11. Daiki Masukawa, Tomohiro Shibata, Koichi Yoshida, Taku Masuda, \bCheng \bChen, Takeshi Tokudome, Atrial natriuretic peptide-signaling in the brain ameliorates the pathogenesis of myocardial infarction model via anti-inflammatory effects\u3001APPW2025\u30012025\u5e743\u670818\u65e5\u30012P-280<\/li>\n\n\n\n
          12. \u5897\u5ddd\u592a\u8f1d\u3001\u67f4\u7530\u667a\u535a\u3001\u5409\u7530\u5149\u4e00\u3001\u5897\u7530\u62d3\u3001\u5fb3\u7559\u5065\u3001\u8133\u5185ANP\u30b7\u30b0\u30ca\u30eb\u306f\u8133\u5185\u708e\u75c7\u6291\u5236\u4f5c\u7528\u3092\u4ecb\u3057\u3066\u5fc3\u7b4b\u6897\u585e\u30e2\u30c7\u30eb\u306e\u75c5\u614b\u3092\u6539\u5584\u3059\u308b\u3001\u7b2c54\u56de\u65e5\u672c\u5fc3\u8108\u7ba1\u4f5c\u52d5\u7269\u8cea\u5b66\u4f1a\u5e74\u4f1a\u30012025\u5e741\u670831\u65e5\u3001Y-2<\/li>\n<\/ol>\n\n\n\n

            2024<\/strong><\/h3>\n\n\n\n

            \u539f\u8457\u8ad6\u6587<\/strong><\/p>\n\n\n\n

              \n
            1. Murakami Y, Katsuchi D, Matsumoto T, Kanazawa K, Shibata T, Kawahara A, Akiba J, Yanaihara N, Okamoto A, Itamochi H, Sugiyama T, Terada A, Nishio S, Tsuda N, Kato K, Ono M, Kuwano M., Y-box binding protein 1\/cyclin A1 axis specifically promotes cell cycle progression at G2<\/sub>\/M phase in ovarian cancer. Sci Rep.<\/em><\/strong>,<\/a> <\/em><\/strong>14(1):21701, 2024.<\/li>\n\n\n\n
            2. Bernstein KE, Cao DY, Shibata T, Saito S, Bernstein EA, Nishi E, Yamashita M, Tourtellotte WG, Zhao TV, Khan Z., Classical and nonclassical effects of angiotensin-converting enzyme: How increased ACE enhances myeloid immune function. J Biol Chem<\/strong><\/em>., 300(6):107388, 2024.<\/li>\n\n\n\n
            3. Tajika R, Masukawa D, Arai M, Nawa H, Goshima Y., Opposite regulation by L-DOPA receptor GPR143 of the long and short forms of the dopamine D2 receptors. J Pharmacol Sci<\/em><\/strong>., 156(1):77-81, 2024.<\/li>\n\n\n\n
            4. Inoue M, Masukawa D, Goshima Y., L-DOPA receptor GPR143 inhibits neurite outgrowth via L-type calcium channels in PC12 cells. J Pharmacol Sci<\/em><\/strong>., 156(1):45-48, 2024.<\/li>\n\n\n\n
            5. Arai M, Suzuki E, Kitamura S, Otaki M, Kanai K, Yamasaki M, Watanabe M, Kambe Y, Murata K, Takada Y, Arisawa T, Kobayashi K, Tajika R, Miyazaki T, Yamaguchi M, Lazarus M, Hayashi Y, Itohara S, d’Exaerde AK, Nawa H, Kim R, Bito H, Momiyama T, Masukawa D, Goshima Y., Enhancement of haloperidol-induced catalepsy by GPR143, an L-DOPA receptor, in striatal cholinergic interneurons. J Neurosci<\/em><\/strong>., 44(11):1504-1523. 2024.<\/li>\n<\/ol>\n\n\n\n

              \u5b66\u4f1a\u767a\u8868<\/strong><\/p>\n\n\n\n

                \n
              1. \u5897\u5ddd\u592a\u8f1d\u3001\u8d64\u5742\u706f\u9999\u3001\u7a0b \u6668\u3001\u5fb3\u7559 \u5065\u3001\u4e2d\u67a2\u795e\u7d4c\u7cfb\u306b\u304a\u3051\u308b\u30a2\u30f3\u30b8\u30aa\u30c6\u30f3\u30b7\u30f3\u2161\u30b7\u30b0\u30ca\u30eb\u306f\u4ea4\u611f\u795e\u7d4c\u6d3b\u6027\u3068\u5fc3\u80a5\u5927\u3092\u4fc3\u9032\u3059\u308b\u3001\u7b2c28\u56de\u65e5\u672c\u5fc3\u8840\u7ba1\u5185\u5206\u6ccc\u4ee3\u8b1d\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012024\u5e7412\u67087\u65e5\u3001P-15<\/li>\n\n\n\n
              2. \u67f4\u7530\u667a\u535a\u3001\u5897\u5ddd\u592a\u8f1d\u3001\u5409\u7530\u5149\u4e00\u3001\u5fb3\u7559\u5065\u3001\u5fc3\u623f\u6027\u30ca\u30c8\u30ea\u30a6\u30e0\u5229\u5c3f\u30da\u30d7\u30c1\u30c9\u306f\u816b\u760d\u8840\u7ba1\u306e\u6b63\u5e38\u5316\u3092\u4fc3\u9032\u3059\u308b\u3001\u7b2c28\u56de\u65e5\u672c\u5fc3\u8840\u7ba1\u5185\u5206\u6ccc\u4ee3\u8b1d\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012024\u5e7412\u67087\u65e5\u3001P-11<\/li>\n\n\n\n
              3. \u5897\u5ddd\u592a\u8f1d\u3001\u67f4\u7530\u667a\u535a\u3001\u5409\u7530\u5149\u4e00\u3001\u5897\u7530\u62d3\u3001\u5fb3\u7559\u5065\u3001ANP \u306e\u8133\u5185\u708e\u75c7\u6291\u5236\u4f5c\u7528\u3092\u5fdc\u7528\u3057\u305f\u5fc3\u7b4b\u6897\u585e\u306e\u753b\u671f\u7684\u6cbb\u7642\u6cd5\u958b\u767a\u3001\u7b2c28\u56de\u65e5\u672c\u5fc3\u8840\u7ba1\u5185\u5206\u6ccc\u4ee3\u8b1d\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012024\u5e7412\u67087\u65e5\u3001YIA2-1<\/li>\n\n\n\n
              4. \u5897\u5ddd\u592a\u8f1d\u3001\u67f4\u7530\u667a\u535a\u3001\u5409\u7530\u5149\u4e00\u3001\u5897\u7530\u62d3\u3001\u5fb3\u7559\u5065\u3001\u4e2d\u67a2\u795e\u7d4c\u7cfb\u306b\u304a\u3051\u308b\u5fc3\u623f\u6027\u30ca\u30c8\u30ea\u30a6\u30e0\u5229\u5c3f\u30da\u30d7\u30c1\u30c9\u30b7\u30b0\u30ca\u30eb\u306f\u5fc3\u7b4b\u6897\u585e\u30e2\u30c7\u30eb\u306e\u75c5\u614b\u3092\u6539\u5584\u3059\u308b\u3001\u7b2c151\u56de\u85ac\u7406\u5b66\u4f1a\u95a2\u6771\u90e8\u4f1a\u30012024\u5e7410\u670812\u65e5\u3001O-4-15<\/li>\n\n\n\n
              5. \u67f4\u7530\u667a\u535a\u3001\u5897\u5ddd\u592a\u8f1d\u3001\u5409\u7530\u5149\u4e00\u3001\u5fb3\u7559\u5065\u3001\u5fc3\u623f\u6027\u30ca\u30c8\u30ea\u30a6\u30e0\u5229\u5c3f\u30da\u30d7\u30c1\u30c9\u306f\u816b\u760d\u5185\u8840\u7ba1\u306e\u6b63\u5e38\u5316\u3092\u8a98\u5c0e\u3059\u308b\u3001\u7b2c151\u56de\u85ac\u7406\u5b66\u4f1a\u95a2\u6771\u90e8\u4f1a\u30012024\u5e7410\u670812\u65e5\u3001O-4-14<\/li>\n\n\n\n
              6. \u8d64\u5742\u706f\u9999\u3001\u7a0b \u6668\u3001\u67f4\u7530\u667a\u535a\u3001\u5409\u7530\u5149\u4e00\u3001\u5897\u7530 \u62d3\u3001\u5897\u5ddd\u592a\u8f1d\u3001\u5fb3\u7559 \u5065\u3001\u8133\u5185\u30a2\u30f3\u30b8\u30aa\u30c6\u30f3\u30b7\u30f3\u2161\u30b7\u30b0\u30ca\u30eb\u306f\u4ea4\u611f\u795e\u7d4c\u6d3b\u6027\u5316\u3068\u5fc3\u80a5\u5927\u3092\u4fc3\u9032\u3059\u308b\u3001\u7b2c151\u56de\u85ac\u7406\u5b66\u4f1a\u95a2\u6771\u90e8\u4f1a\u30012024\u5e7410\u670812\u65e5\u3001O-4-01<\/li>\n\n\n\n
              7. \u5fb3\u7559\u5065\u3001\u30da\u30d7\u30c1\u30c9\u30db\u30eb\u30e2\u30f3\u306e\u30c8\u30e9\u30f3\u30b9\u30ec\u30fc\u30b7\u30e7\u30ca\u30eb\u30ea\u30b5\u30fc\u30c1\u3068\u5275\u85ac\u3001\u7b2c150\u56de\u85ac\u7406\u5b66\u4f1a\u95a2\u6771\u90e8\u4f1a\u30012024\u5e746\u670829\u65e5\u3001\u6559\u80b2\u8b1b\u6f143<\/li>\n<\/ol>\n\n\n\n

                2023<\/strong><\/h3>\n\n\n\n

                \u539f\u8457\u8ad6\u6587<\/strong><\/p>\n\n\n\n

                  \n
                1. Masukawa D, Takahagi R, Nakao Y, Goshima Y., L-DOPA Receptor GPR143 Functionally Couples with Adrenergic \u03b11B<\/sub> Receptor at the Second Transmembrane Interface. Biol Pharm Bull<\/em>.<\/strong>, 46(7):869-873, 2023.<\/li>\n\n\n\n
                2. Sugioka S, Yamada H, Ishii A, Kato Y, Yamada R, Mori KP, Ohno S, Handa T, Ikushima A, Ishimura T, Osaki K, Tokudome T, Matsusaka T, Nebreda AR, Yanagita M, Yokoi H., Dual deletion of guanylyl cyclase-A and p38 mitogen-activated protein kinase in podocytes with aldosterone administration causes glomerular intra-capillary thrombi. Kidney Int.<\/em><\/strong>, S0085-2538(23)00425-8, 2023.<\/li>\n\n\n\n
                3. Uchimura H, Kanai K, Arai M, Inoue M, Hishimoto A, Masukawa D, Goshima Y., Involvement of the L-DOPA receptor GPR143 in acute and chronic actions of methylphenidate. J Pharmacol Sci<\/em>.<\/strong>, 165(2):177-195, 2023.<\/li>\n\n\n\n
                4. Masukawa D, Kitamura S, Tajika R, Uchimura H, Arai M, Takada Y, Arisawa T, Otaki M, Kanai K, Kobayashi K, Miyazaki T, Goshima Y., Coupling between GPR143 and dopamine D2 receptor is required for selective potentiation of dopamine D2 receptor function by L-3,4-dihydroxyphenylalanine in the dorsal striatum. J Neurochem<\/em>.<\/strong>, 165(2):177-195, 2023.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

                  \u7814\u7a76\u696d\u7e3e 2026 \u539f\u8457\u8ad6\u6587 \u5b66\u4f1a\u767a\u8868 2025 \u539f\u8457\u8ad6\u6587 \u7dcf\u8aac \u5b66\u4f1a\u767a\u8868 2024 \u539f\u8457\u8ad6\u6587 \u5b66\u4f1a\u767a\u8868<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-21","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www-user.yokohama-cu.ac.jp\/~pharmac\/wp-json\/wp\/v2\/pages\/21","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www-user.yokohama-cu.ac.jp\/~pharmac\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www-user.yokohama-cu.ac.jp\/~pharmac\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www-user.yokohama-cu.ac.jp\/~pharmac\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www-user.yokohama-cu.ac.jp\/~pharmac\/wp-json\/wp\/v2\/comments?post=21"}],"version-history":[{"count":66,"href":"https:\/\/www-user.yokohama-cu.ac.jp\/~pharmac\/wp-json\/wp\/v2\/pages\/21\/revisions"}],"predecessor-version":[{"id":735,"href":"https:\/\/www-user.yokohama-cu.ac.jp\/~pharmac\/wp-json\/wp\/v2\/pages\/21\/revisions\/735"}],"wp:attachment":[{"href":"https:\/\/www-user.yokohama-cu.ac.jp\/~pharmac\/wp-json\/wp\/v2\/media?parent=21"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}